Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00003344 · ClinicalTrials.gov registry record · Phase 1

Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer

A Phase 1 study of Colorectal Cancer, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 1
Development phase
49
Enrollment target
1
Study location

NCT00003344: Completed Phase 1 study of Colorectal Cancer, sponsored by Medical University of South Carolina.

NCT00003344 is a Phase 1 study of Colorectal Cancer that has completed, run by Medical University of South Carolina. The registered enrollment target is 49 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00003344, a Phase 1 study of Colorectal Cancer, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 1
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy plus irinotecan in treating patients with colon cancer that is recurrent or that cannot be removed surgically.

Conditions Studied

Interventions

  • RADIATION radiation therapy
  • DRUG irinotecan hydrochloride

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 1998-08
Est. Completion 2000-01
Phase Phase 1

What the finished NCT00003344 record still lists

NCT00003344 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.

NCT00003344 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT00003344 about?

NCT00003344 is a clinical study titled "Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer". RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the ef...

What is the current status of trial NCT00003344?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 1998-08. Estimated completion is 2000-01.

What conditions does trial NCT00003344 study?

This clinical trial studies the following conditions: Colorectal Cancer.

What interventions are being tested in trial NCT00003344?

The interventions under investigation include: radiation therapy (RADIATION), irinotecan hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00003344?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00003344 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00003344's enrollment target sits among peer trials

49 275th of 381 higher than 106 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00003344, the US trial registry maintained by the National Library of Medicine. NCT00003344 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.